ArticleBriefings in bioinformatics2026
Integrated machine learning and molecular dynamics framework for predicting and elucidating ABCB1 allocrite interactions.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
ABCB1, a polyspecific efflux transporter, mediates multidrug resistance in cancer by interacting with diverse substrates and inhibitors, yet its recognition mechanisms remain elusive. Here, we introduce an integrated framework that synergistically combines biophysics and computational biology to predict ABCB1 allocrite interactions and elucidate their mechanisms. We curated hierarchical-confidence bioactivity datasets from multi-source assays and developed MolMM, a convolutional neural network leveraging meta-learning on noisy data and multi-task learning on refined data, achieving AUC-ROC scores of 83.33% for inhibitors and 81.26% for substrates. SHapley Additive exPlanations (SHAP) analysis revealed key molecular features, highlighting competitive polar, and hydrophobic motifs distinguishing substrates from inhibitors . Building on these ML insights, coarse-grained umbrella sampling simulations mapped these features onto free energy landscapes, proposing an amphiphilic model for substrate binding via a flip-flop process through the transmembrane pore and an inhibitory mechanism stabilizing ABCB1 in transitional conformations at the cavity's gate. This machine learning-molecular dynamics synergy offers mechanistic insights into ABCB1 polyspecificity, facilitating rational design of inhibitors to overcome multidrug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.